Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

IBM Launches New Health Unit, Teams With Apple, J&J, Medtronic

The Watson Health unit will aggregate data from users’ devices, then sell insights to health care companies.

IBM

IBM, deepening its partnership with Apple to make use of health information gathered by millions of Apple devices, is creating a unit dedicated to providing data analytics to the health care sector.

Its new Watson Health unit plans to aggregate health information from a large number of devices and providers in the cloud and offer insights to health companies such as Johnson & Johnson and Medtronic, which can then integrate results into services they sell to health care companies.

IBM said it will create headquarters for the unit in Boston with 2,000 employees, including about 75 medical practitioners. IBM also said it bought two health technology firms, Explorys and Phytel, for an undisclosed amount, to add to its skills in health data analytics.

IBM already has an arrangement to work with Apple on numerous enterprise applications, but is extending its co-operation in the area of health.

Watson Health — named for IBM’s artificial intelligence creation, which beat previous champions of the quiz show “Jeopardy” — will bring cloud services and analytics to Apple’s latest forays into the health business, HealthKit and ResearchKit.

HealthKit centralizes a user’s health data provided by any number of fitness and health apps on a device, while ResearchKit is an open-source platform that lets researchers create diagnostic apps for use on the iPhone. One example is mPower, which measures hand tremors as a test for Parkinson’s disease.

Both services generate millions of points of data, and with customers’ consent, IBM is looking to turn that anonymous data into meaningful signals for the treatment of illnesses or rehabilitation.

Johnson & Johnson, for example, said it will work with IBM on mobile-based coaching systems to help patients before or after surgery and will launch new health apps targeting chronic conditions.

Medical device maker Medtronic said it will use insights from Watson Health and work with IBM on personalized care plans for people with diabetes.

(Reporting by Bill Rigby; Editing by Dan Grebler)

This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh